Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.37 on Thursday. The firm’s 50 day simple moving average is $1.99 and its two-hundred day simple moving average is $3.83. Evogene has a one year low of $1.26 and a one year high of $10.40. The stock has a market capitalization of $7.36 million, a P/E ratio of -0.31 and a beta of 1.36.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.